American Association for Cancer Research

sorry, we can't preview this file

23266066cir200964-sup-255948_3_supp_7254280_qw7t1y.docx (59.72 kB)

Supplementary Legends from CD8+ T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA PVT1

Download (59.72 kB)
journal contribution
posted on 2023-04-04, 01:20 authored by Yasuhiro Kikuchi, Serina Tokita, Tomomi Hirama, Vitaly Kochin, Munehide Nakatsugawa, Tomoyo Shinkawa, Yoshihiko Hirohashi, Tomohide Tsukahara, Fumitake Hata, Ichiro Takemasa, Noriyuki Sato, Takayuki Kanaseki, Toshihiko Torigoe

Supplementary Information


Japan Agency for Medical Research and Development

Grant-in-Aid for Scientific Research

Japan Society for the Promotion of Science

Takeda Science Foundation



CD8+ T cells recognize peptides displayed by HLA class I molecules on cell surfaces, monitoring pathologic conditions such as cancer. Advances in proteogenomic analysis of HLA ligandomes have demonstrated that cells present a subset of cryptic peptides derived from noncoding regions of the genome; however, the roles of cryptic HLA ligands in tumor immunity remain unknown. In the current study, we comprehensively and quantitatively investigated the HLA class I ligandome of a set of human colorectal cancer and matched normal tissues, showing that cryptic translation products accounted for approximately 5% of the HLA class I ligandome. We also found that a peptide encoded by the long noncoding RNA (lncRNA) PVT1 was predominantly enriched in multiple colorectal cancer tissues. The PVT1 gene is located downstream of the MYC gene in the genome and is aberrantly overexpressed across a variety of cancers, reflecting its oncogenic property. The PVT1 peptide was recognized by patient CD8+ tumor-infiltrating lymphocytes, as well as peripheral blood mononuclear cells, suggesting the presence of patient immune surveillance. Our findings show that peptides can be translated from lncRNAs and presented by HLA class I and that cancer patient T cells are capable of sensing aberrations in noncoding regions of the genome.

Usage metrics

    Cancer Immunology Research



    Ref. manager